Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. September 2016 07:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016

FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
12. September 2016 19:07 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference

FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
22. August 2016 11:02 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016

FRAMINGHAM, MA--(Marketwired - Aug 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
19. August 2016 08:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire

FRAMINGHAM, MA--(Marketwired - Aug 19, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of devices for use in controlling bleeding and fluid loss in order...
15. August 2016 06:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study

FRAMINGHAM, MA--(Marketwired - Aug 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
06. Juni 2016 07:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5

FRAMINGHAM, MA--(Marketwired - Jun 6, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
27. Mai 2016 09:00 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement

FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
16. Mai 2016 07:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics

FRAMINGHAM, MA--(Marketwired - May 16, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use...
10. Mai 2016 08:00 ET | Quelle: Nu-Med Plus, Inc.

Nu-Med Plus Announces Investigational Study of Stored Blood as a New Path for Their NO Devices

SALT LAKE CITY, UT--(Marketwired - May 10, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announces they are embarking on a new investigational study applying...
10. Mai 2016 07:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides

FRAMINGHAM, MA--(Marketwired - May 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...

Vorherige Seite

Nächste Seite